Patents Examined by Patrick J. Nolan
  • Patent number: 7776340
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 17, 2010
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Patent number: 7776523
    Abstract: Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 17, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Pablo D. Garcia, Stephen F. Hardy, Jaime Escobedo, Lewis T. Williams
  • Patent number: 7758867
    Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: July 20, 2010
    Assignee: Biotrion Co., Ltd.
    Inventors: Baik Lin Seong, Kwang Hee Lee, Sang Uk Seo
  • Patent number: 7741453
    Abstract: The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 22, 2010
    Assignee: Conjuchem Biotechnologies, Inc.
    Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer
  • Patent number: 7740855
    Abstract: A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: June 22, 2010
    Assignees: Yeda Research & Development Co. Ltd, Hadasit Medical Research Services and Dev. Ltd
    Inventors: Rivka Abulafia-Lapid, Henri Atlan, Irun R. Cohen
  • Patent number: 7736642
    Abstract: The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: June 15, 2010
    Assignee: GlobeImmune, Inc.
    Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King, Yingnian Lu, Victoria Kelley Hodson
  • Patent number: 7189812
    Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater genomic, cDNA and protein sequences are provided, as are fragments and variants thereof. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for using Mater molecules in diagnoses, prognosis, and treatment of infertility and reduced fertility, and kits related to such methods. Also provided are methods for using MATER as a contraceptive agent. The disclosure also describes compounds involved in such methods, and the identification of such compounds.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: March 13, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Lawrence M. Nelson, Zhi-Bin Tong
  • Patent number: 7157500
    Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: January 2, 2007
    Assignee: Brigham and Women's Hospital
    Inventors: Jonathan Stamler, Joseph Loscalzo, Daniel Simon, David Singel
  • Patent number: 7128921
    Abstract: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 31, 2006
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Shirley Wu Hunter, Eric R. Weber
  • Patent number: 7122336
    Abstract: This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: October 17, 2006
    Assignee: University of Medicine & Dentistry of New Jersey
    Inventor: Kiron M. Das
  • Patent number: 7112325
    Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme, antibodies to such enzyme, and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: September 26, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Simon Jones, Jin Tang
  • Patent number: 7112438
    Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: September 26, 2006
    Assignee: Dyax Corp.
    Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
  • Patent number: 7109306
    Abstract: The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Antibodies to human HOIPS I are also provided, as are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: September 19, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Steven M. Ruben
  • Patent number: 7108858
    Abstract: The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: September 19, 2006
    Assignee: Pharmacia Diagnostics AB
    Inventors: Rudolf Valenta, Susanne Vrtala, Luca Vangelista, Hans-Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Hans Grönlund
  • Patent number: 7101962
    Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Burke, Violetta Iotzova
  • Patent number: 7098316
    Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: August 29, 2006
    Assignees: Human Genome Sciences, Inc., Auckland Uniservices, Limited
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Jeffrey Y. Su, Geoffrey Krissansen, Ping Feng
  • Patent number: 7094890
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of cartilage degenerative conditions, including forms of arthritis. In particular, the invention relates to a protein, termed “adlican,” that is differentially transcribed and expressed in human subjects suffering from arthritis, such as osteoarthritis (OA) and rheumatoid arthritis (RA) compared with non-arthritis sufferers, antibodies which recognize this protein, and methods for diagnosing arthritis.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 22, 2006
    Assignee: Novartis AG
    Inventors: Robert Mitchell Crowl, Daniel C. Luk
  • Patent number: 7094561
    Abstract: The present invention relates to methods of monitoring the menstrual cycle and/or the first half of pregnancy in a female by assessing the adhesion of lymphocytes from the female to uterine or lymphoid histological tissues from a pregnant animal or an animal that has been treated with gestational hormones. The method can be used to determine the ability of the lymphocyte donor's immune system to recognize and respond to an environment suitable for sustaining a pregnancy.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: August 22, 2006
    Assignees: University of Guelph, Health Research, Inc., Roswell Park Division
    Inventors: Barbara Anne Croy, Sharon S. Evans
  • Patent number: 7087726
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: August 8, 2006
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • Patent number: 7084260
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: October 10, 1996
    Date of Patent: August 1, 2006
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild